Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...

A group of researchers in Japan says it has confirmed a certain level of efficacy in using iPS cell-derived immune cells for ...

Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...

bit.bio's ioSensory Neurons pain research was selected for presentation at SfN’s Neuroscience 2024 press conference, and it was chosen from over 10,500+ submissions. bit.bio will host an expert panel ...

Alongside the complete kit, TheWell Bioscience has released the RocketCell (TM) iPSC Xeno-Free Growth Medium. Available as a standalone product, this xeno-free medium is designed for researchers who ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...

Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data ...

Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma Patient-specific human immune system-bearing mouse ...

As of Thursday, January 08, Century Therapeutics, Inc.’s IPSC share price has surged by 30.65%, which has investors ...

A Beachwood-based biotechnology company has secured $20 million, expanding financing for the company to $40 million.